Inventor · disambiguated record
Steven Lacy
Also filed as: LACY STEVEN
5 granted patents·9 pending applications·48 citations·filing 2014–2024
80Inventor score
Files withEXELIXIS INC14
Top patents by PatentIndex Score
14 records- 0194US10159666B2Dosing of cabozantinib formulationsEXELIXIS INC·Filed 2015·Granted Dec 25, 2018·21 cites·8 claims
- 0292US10273211B2Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamideEXELIXIS INC·Filed 2014·Granted Apr 30, 2019·17 cites·2 claims
- 0391US12016854B2Liquid dosage forms to treat cancerEXELIXIS INC·Filed 2022·Granted Jun 25, 2024·1 cites·7 claims
- 0490US11141413B2Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioateEXELIXIS INC·Filed 2017·Granted Oct 12, 2021·8 cites·21 claims
- 0585US2024287002A1Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamideEXELIXIS INC·Filed 2024·Application pending·0 cites
- 0681US11504362B2Liquid dosage forms to treat cancerEXELIXIS INC·Filed 2018·Granted Nov 22, 2022·1 cites·13 claims
- 0778US2024307367A1Liquid Dosage Forms to Treat CancerEXELIXIS INC·Filed 2024·Application pending·0 cites
- 0877US2024350477A1Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioateEXELIXIS INC·Filed 2023·Application pending·0 cites
- 0973US2022401433A1Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioateEXELIXIS INC·Filed 2022·Application pending·0 cites
- 1072US2021002228A1Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamideEXELIXIS INC·Filed 2020·Application pending·0 cites
- 1169US2023045783A9Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioateEXELIXIS INC·Filed 2021·Application pending·0 cites
- 1262US2020163954A1Dosing of Cabozantinib FormulationsEXELIXIS INC·Filed 2020·Application pending·0 cites
- 1361US2019218182A1Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamideEXELIXIS INC·Filed 2019·Application pending·0 cites
- 1456US2019076420A1Dosing of Cabozantinib FormulationsEXELIXIS INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Steven Lacy files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →